A Phase III clinical trial of a new antibiotic He found that it works exactly like a current drug shape to treat gonorrhea infections. This is especially important because gonorrhea bacteria have become resistant to most existing antibiotics.
Gonorrhea is the second most common bacterial Sti that refers to the United States. There were over 600,000 cases of gonorrhea diagnosed in this country in 2023. Because so many cases of gonorrhea have no symptoms, many people are never tested. It is likely that there are many more annual cases. In fact, the CDC estimates that there is actually a 1.6 million case each year. The World Health Organization (WHO) appreciates more than 80 million new cases worldwide.
We were able to cure gonorrhea from the introduction of antibiotics about a century ago, but we are exhaustion of the drugs. Neisseria gonorrhoeaeThe bacterium caused by this common Sti has changed steadily to avoid entire classes of antibiotics. Already in the 1940s, bacteria were resistant to sulfanilamides. Until the 1980s it was resistant to penicillins and tetihynclins. In 2007, the CDC stopped being fluoroquinolones, these means that cephalosporins as an effective treatment against this Stii common.
Today, most people with simple gonorrhea receive a single dose of CEFTRIAXONE (which is a cephalosporin). Some also receive a dose of oral azithromycin. There have been cases in several countries where this treatment alone was not enough. These patients had to get a combination of existing antibiotics. Public health experts are afraid that the bacteria will eventually develop resistance to Cephalosporins and we will have no new antibiotics to take their place. Fortunately, there are some new options in growth.
The newest antibiotic is called Gepotidacin. It was recently approved by the FDA for the treatment of urinary tract infections. (UTIS antibiotic -resistant have also increased in recent years.) Experts believe they will also be successful against gonorrhea.
For this test, the researchers recruited 600 people aged 12 years and over who had been diagnosed with gonorrhea gene infection. Participants were from Australia, Germany, Mexico, Spain, the United Kingdom and the United States. About half of the participants received a shot of 500 mg from cefitraxon followed by an azithromycin dose. The other half received from the gepotidacin oral. This team took two 3,000mm pills that gave about 12 hours.
The two shapes had very similar results for patients with genital parenting: 92.6% of the Gepotidacin group was cured compared to 91.2% of those treated with ceftriaxone co -azithromycin. Gepotidacin was effective against gonorrhea executives known to have been resistant to existing antibiotics.
There were some differences. The group that took the new oral medicine had more gastrointestinal side effects such as nausea and diarrhea.
This clinical trial focused on the treatment of urogenital gonorrhea which means infections of the vulva, vagina, cervix, penis and urethra. However, gonorrhea can also infect the anus and throat. Some participants in this study had infections from gonorrhea in their throat or rectum. Gapotidacin was able to cure some of these infections, although the researchers did not have enough data to really analyze the results. They had full data for 16 participants with throat gonorrhea and were able to find that 14 of them were healed. This is a good result, since throat infections are known to be more difficult to deal with.
In addition, Gepotidacin is one of the oral medicine. This means that people do not need to go to a healthcare office to get a treatment they do for a shot. This opens other options such as telecommunications recipes that can be easier for people to use. It also allows providers to offer rapid partners therapy (EPT). In order to stop the spread of gonorrhea, it is important to deal with all the partners that can be infected. EPT is a way to get treatment for a patient’s partner without the need to see it from the provider himself. Research has found that EPT significantly reduces the likelihood of recurrence.
As Ashaha said earlier, there is another new drug called Zoliflodacin, which also had a success against gonorrhea in a clinical trial. The introduction of new treatments that can help us fight antibiotic resistance is a great news for patients and providers.
